Pharmabiz5h
Qiagen increases QIAcuity Digital PCR High-Order Multiplexing capabilities to gain deeper insights from biological samples
Venlo, Netherlands Monday, January 13, 2025, 17:00 Hrs [IST] ...
Pharmabiz7h
ProMIS Neurosciences begins PRECISE-AD phase 1b trial of lead therapeutic candidate, PMN310 in Alzheimer’s disease
Cambridge, Massachusetts Monday, January 13, 2025, 15:00 Hrs [IST] ...
Pharmabiz5h
Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia
Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia: San Diego Monday, January 13, 2025, 16:30 Hrs [IST] Crinetics Pharmac ...
Pharmabiz6h
NIHR-funded research shows AI may help doctors improve the success rates of IVF treatment
NIHR-funded research shows AI may help doctors improve the success rates of IVF treatment: United Kingdom Monday, January 13, 2025, 16:00 Hrs [IST] NIHR-funded research has discov ...
Pharmabiz6d
Indian healthcare sees medical networking as catalyst for quality services in remote regions
The Indian healthcare sector sees emergence of medical networking to revolutionise quality services in remote regions. This is despite the resource and infrastructural constraints leading to the ...
Pharmabiz5h
Lupin introduces Minzoya in US market
Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved Minzoya (levonorgestrel and ethinyl estradiol tablets, USP and ferrous ...
Pharmabiz6d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in countries where the product is not ...
Pharmabiz9d
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy
Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced the completion of the submission of its ...
Pharmabiz7d
Eton Pharma acquires Galzin, an US FDA approved treatment of ultra-rare metabolic condition of Wilson disease
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate). “This ...
Pharmabiz7d
Parliamentary panel asks DoE to furnish justification on denying proposal for setting up of NIMERs
Expressing its concern over the Department of Expenditure's (DoE) decision to turn down the Department of Pharmaceuticals (DoP)’s proposal for setting up separate National Institutes for Medical ...
Pharmabiz9d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Pharmabiz7d
Bayer announces Federal Court of Australia brings an end to Roundup litigation
The Federal Court of Australia brought an end to the last Roundup case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs’ request to discontinue the Fenton ...